G. Dane
GlaxoSmithKline (United Kingdom) · 15 works · 1,275 citations · h-index 8
Top works
- Phase III Trial Comparing Supportive Care Alone With Supportive Care With Oral Topotecan in Patients With Relapsed Small-Cell Lung Cancer
- Phase III Study of Oral Compared With Intravenous Topotecan As Second-Line Therapy in Small-Cell Lung Cancer
- Phase III Study Comparing Oral Topotecan to Intravenous Docetaxel in Patients With Pretreated Advanced Non–Small-Cell Lung Cancer
- Evidence for homogeneity of thromboxane A2 receptor using structurally different antagonists
- O-157 Survival benefit of oral topotecan plus supportive care versus supportive care alone in relapsed, resistant SCLC
- Oral topotecan demonstrates clinical activity in relapsed non-small cell lung cancer. Results from an open-label, phase III study (387) comparing oral topotecan to intravenous docetaxel
- 41 Preliminary results of a randomized comparative phase III trial of topotecan (T) versus CAV as second-line therapy of small cell lung cancer (SCLC)
- P-569 The relationship between treatment-free interval (TFI) and outcomes to therapy in patients with relapsed Small Cell Lung Cancer (SCLC): A review of 631 patients treated with IV topotecan in 6 studies
- P-568 Correlation between response, treatment duration, and median survival. Single agent intravenous (IV) topotecan in a population of 631 relapsed Small Cell Lung Cancer (SCLC) patients
- Phase II trial of topotecan (T) as a continuous intravenous infusion in patients (PTS) with high grade gliomas
- Long-term survival in a phase III randomised study of topotecan (T) vs paclitaxel (P) in advanced epithelial ovarian carcinoma
- 775 Standards of care for patients with small cell lung cancer (SCLC): a survey of clinical practice within the European Union (EU)
- Preliminary results of a randomised comparative phase III trial of topotecan versus CAV as second-line therapy of small cell lung cancer
- The relationship between tumour response, stabilisation of disease and survival: A meta-analysis of two Phase III studies on topotecan in relapsed ovarian cancer
- The relationship between tumour response, stabilisation of disease and survival: A meta-analysis of two Phase III studies on topotecan in relapsed ovarian cancer